(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 6.88% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Merck & Co's revenue in 2024 is $60,115,000,000.On average, 7 Wall Street analysts forecast MRK's revenue for 2024 to be $161,958,688,006,056, with the lowest MRK revenue forecast at $159,754,110,158,016, and the highest MRK revenue forecast at $164,156,675,914,742. On average, 7 Wall Street analysts forecast MRK's revenue for 2025 to be $174,010,347,317,641, with the lowest MRK revenue forecast at $168,682,606,754,473, and the highest MRK revenue forecast at $179,898,759,515,904.
In 2026, MRK is forecast to generate $185,870,381,728,582 in revenue, with the lowest revenue forecast at $177,085,551,888,408 and the highest revenue forecast at $193,230,596,858,112.